RxDoctor Payments Data

Richard Antosek, DO

Urology · Sunrise, FLNPI 1912993536

Payments from drug & device makers

$14,105in general payments, 2019–2025

Across 94 payments — averaging $150.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$12K
  • Johnson & Johnson$575
  • Myriad Genetic Laboratories, Inc.$569
  • Rochester Medical Corporation$193
  • Myovant Sciences Inc.$139
  • Olympus America Inc.$139
  • plus $520 from 10 others

What the payments were for

  • Speaking & faculty fees$11,04578%
  • Food & beverage$2,91021%
  • Education$1501%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,105 in reported general payments places this provider in the 75th percentile of 935 urology providers in Florida.

See all urology providers in Florida

Medicare billing

Part B allowed, 2024
$18,004
Medicare patients
97
Services billed
240

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lupron DepotLeuprolide Acetate57$343,361
Thiola EcTiopronin12$274,738
GemtesaVibegron218$147,940
MyrbetriqMirabegron146$126,844
EligardLeuprolide Acetate37$50,586
Tamsulosin Hcl687$10,161
Solifenacin Succinate185$7,961
Potassium Citrate ErPotassium Citrate51$5,993
NitrofurantoinNitrofurantoin Macrocrystal73$5,037
Methenamine Hippurate52$3,353
Finasteride268$3,228
Oxybutynin Chloride ErOxybutynin Chloride218$3,121
Testosterone33$2,766
Alfuzosin Hcl ErAlfuzosin Hcl123$1,818
Desmopressin Acetate28$1,533

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$11,969$126,844146 claims
Tolmar Pharmaceuticals, Inc.Eligard$19$50,58637 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 935 urology providers in Florida.

Other urology in Sunrise

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →